By Craig T. Zebuda, MD, DipACLM
Chief Medical Officer, Yunara Life
Over the past year, I’ve watched peptides become part of almost every conversation about longevity and healthy aging.
Patients ask about them during routine visits. Friends bring them up over dinner. Podcasts discuss them as though they represent the next major breakthrough in preventive health. By the time many people sit down in my office, they’ve already spent hours researching online and are trying to sort through a mix of scientific studies, personal anecdotes, marketing claims, and social media opinions.
I understand the interest.
Medicine has a long history with peptide-based therapies that have had a meaningful impact on patient care. GLP-1 medications are probably the most visible recent example, but others include standard treatments like insulin, glucagon, and oxytocin. Research continues in areas ranging from hormone regulation and body composition to recovery and age-related conditions, and there is genuine scientific excitement surrounding some of that work.
What I often find myself doing during these conversations is adding context.
The word “peptide” sounds like a single category, but in practice it encompasses a wide range of therapies with varying levels of evidence, regulation, and clinical experience behind them. While some have been extensively studied and are prescribed routinely, others remain investigational. Some are supported by years of clinical data and others are being discussed publicly long before we have definitive answers.
Most patients are not expected to know where those lines are, which is one reason these conversations benefit from the involvement of a knowledgeable healthcare professional.
If a member of my own family asked me whether they should consider peptide therapy, my first questions would be fairly simple. What are you hoping to accomplish? Who is recommending it? What evidence supports it? And where is it coming from? That last question deserves much more attention than it gets.
Much of the public conversation focuses on outcomes. People naturally want to know whether a particular therapy works. Physicians spend a great deal of time thinking about prescribing practices and patient safety because those factors influence outcomes as much as the medication itself.
Patients should know where their medications come from. They should feel comfortable asking who manufactures them, how they are sourced, and what safeguards are in place to ensure quality and consistency. This addresses the very real risks of dangerous contamination and mislabeled dosing and ingredients. The FDA’s guidance on compounded medications is a useful place to start for anyone trying to understand how medications are produced and regulated.
Over the course of my career, I’ve seen countless health trends come and go. Some ultimately changed the way we practice medicine. Others generated far more excitement than evidence. The challenge is that enthusiasm almost always arrives before certainty. That doesn’t mean patients should dismiss new therapies. It means they should approach them with curiosity, healthy skepticism, and a willingness to ask thoughtful questions.
The people who age well are rarely using a single intervention that will solve everything. They are usually building upon a strong foundation that includes movement, sleep, nutrition, preventive care, and meaningful social connection. Organizations such as the American College of Lifestyle Medicine have spent years building the evidence base around these behaviors because they continue to influence health outcomes regardless of what new therapies emerge.
The science around peptides will continue to evolve, and I expect we’ll learn a great deal in the years ahead. For now, the advice I would give my own family is the same advice I give my patients: work with clinicians you trust, ask questions about evidence and sourcing and be wary of anyone who claims to have all the answers in a field that is still rapidly developing.